High cholesterol is often dubbed the “silent killer” because it progresses for years without clear symptoms, until serious ...

Arcus senilis is caused due to the lipid build-ups in the cornea's blood vessels around the iris, which is a clear indication of declining cardiovascular health. Retinal vein occlusion (Blocked ...

A soft, gray ring around the cornea (Arcus Senilis) This ring around the iris is considered a harmless part of getting older. Known as arcus senilis, it’s made of lipid (fat) deposits.

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biopharmaceutical company focused on developing innovative cancer therapies, stands at a critical juncture in its journey to bring novel treatments to ...

Measurements of the curvature of the cornea of the eye can be significantly affected by the status of dry eye in a patient, according to a study published in Frontiers in Medicine. 1 Different ...

Corneal disease in patients with VKC and AKC ranges from Tranta's dots, superficial punctuate keratitis, shield ulcer, ... Pseudogerontoxon, which resembles arcus senilis, ...

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes ...

Under the terms of the deal, Arcus received $375 million upfront, with another $1.225 billion in opt-in and milestone payments tied to clinical-stage candidates, which also include AB680, a small ...

Pseudogerontoxon, which resembles arcus senilis, is a waxing and waning grey-white lipid deposition in the superficial stroma of the peripheral cornea. It is an uncommon complication of VKC, and, ...

Gilead and Arcus entered into a $2 billion alliance in 2021 in which Gilead exercised options on four drug candidates, including domvanalimab, follow-up TIGIT AB308, adenosine A2a/A2b receptor ...

Review which funds and institutions currently hold Arcus Biosciences Inc (RCUS:XNYS) stock for ownership information.